Vaccine protection of rhesus macaques against simian immunodeficiency virus infection

J. R. Carlson, T. P. McGraw, E. Keddie, J. L. Yee, A. Rosenthal, Paul A Luciw, R. Dickover, R. Donovan, P. A. Luciw, M. B. Jennings, M. B. Gardner

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Rhesus macaques (Macaca mulatta) immunized with an inactivated whole SIV(mac) vaccine and muramyl dipeptide (MDP), incomplete Freund's adjuvant (IFA), or aqueous suspension were challenged intravenously with 0.1 TCID50 of cell-free SIV(mac). Whereas virus was readily recovered from the peripheral blood lymphocytes of 10 of 10 nonvaccinated controls following this challenge dose, virus was not recovered from the three animals that received the vaccine with MDP nor from one of two animals that received the vaccine with IFA and one of three animals that received the aqueous vaccine. The animals that were protected against challenge were those that had detectable SIV antibody response to the envelop, both the outer glycoprotein (gp120) and the truncated transmembrane glycoprotein (gp31). Protected monkeys tended to have higher titers of syncytial inhibition antibody prior to challenge. An anamnestic response after challenge was observed only in the vaccinated monkeys that became infected. Vaccinated animals that became challenge-infected tended to live longer than infected controls. These results confirm those at two other primate centers and indicate that killed whole SIV vaccines can protect against low challenge doses of SIV and prevent early death in those monkeys that do become infected. The mechanism of this protection remains undetermined. This finding adds optimism to the possibility of an eventual AIDS vaccine.

Original languageEnglish (US)
Pages (from-to)1239-1246
Number of pages8
JournalAIDS Research and Human Retroviruses
Volume6
Issue number11
StatePublished - 1990

Fingerprint

Simian Immunodeficiency Virus
Virus Diseases
Macaca mulatta
Vaccines
SAIDS Vaccines
Acetylmuramyl-Alanyl-Isoglutamine
Haplorhini
Glycoproteins
Viruses
AIDS Vaccines
Primates
Antibody Formation
Suspensions
Lymphocytes
Antibodies

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Carlson, J. R., McGraw, T. P., Keddie, E., Yee, J. L., Rosenthal, A., Luciw, P. A., ... Gardner, M. B. (1990). Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Research and Human Retroviruses, 6(11), 1239-1246.

Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. / Carlson, J. R.; McGraw, T. P.; Keddie, E.; Yee, J. L.; Rosenthal, A.; Luciw, Paul A; Dickover, R.; Donovan, R.; Luciw, P. A.; Jennings, M. B.; Gardner, M. B.

In: AIDS Research and Human Retroviruses, Vol. 6, No. 11, 1990, p. 1239-1246.

Research output: Contribution to journalArticle

Carlson, JR, McGraw, TP, Keddie, E, Yee, JL, Rosenthal, A, Luciw, PA, Dickover, R, Donovan, R, Luciw, PA, Jennings, MB & Gardner, MB 1990, 'Vaccine protection of rhesus macaques against simian immunodeficiency virus infection', AIDS Research and Human Retroviruses, vol. 6, no. 11, pp. 1239-1246.
Carlson, J. R. ; McGraw, T. P. ; Keddie, E. ; Yee, J. L. ; Rosenthal, A. ; Luciw, Paul A ; Dickover, R. ; Donovan, R. ; Luciw, P. A. ; Jennings, M. B. ; Gardner, M. B. / Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. In: AIDS Research and Human Retroviruses. 1990 ; Vol. 6, No. 11. pp. 1239-1246.
@article{58aaa75ff1224cad934e638029102271,
title = "Vaccine protection of rhesus macaques against simian immunodeficiency virus infection",
abstract = "Rhesus macaques (Macaca mulatta) immunized with an inactivated whole SIV(mac) vaccine and muramyl dipeptide (MDP), incomplete Freund's adjuvant (IFA), or aqueous suspension were challenged intravenously with 0.1 TCID50 of cell-free SIV(mac). Whereas virus was readily recovered from the peripheral blood lymphocytes of 10 of 10 nonvaccinated controls following this challenge dose, virus was not recovered from the three animals that received the vaccine with MDP nor from one of two animals that received the vaccine with IFA and one of three animals that received the aqueous vaccine. The animals that were protected against challenge were those that had detectable SIV antibody response to the envelop, both the outer glycoprotein (gp120) and the truncated transmembrane glycoprotein (gp31). Protected monkeys tended to have higher titers of syncytial inhibition antibody prior to challenge. An anamnestic response after challenge was observed only in the vaccinated monkeys that became infected. Vaccinated animals that became challenge-infected tended to live longer than infected controls. These results confirm those at two other primate centers and indicate that killed whole SIV vaccines can protect against low challenge doses of SIV and prevent early death in those monkeys that do become infected. The mechanism of this protection remains undetermined. This finding adds optimism to the possibility of an eventual AIDS vaccine.",
author = "Carlson, {J. R.} and McGraw, {T. P.} and E. Keddie and Yee, {J. L.} and A. Rosenthal and Luciw, {Paul A} and R. Dickover and R. Donovan and Luciw, {P. A.} and Jennings, {M. B.} and Gardner, {M. B.}",
year = "1990",
language = "English (US)",
volume = "6",
pages = "1239--1246",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Vaccine protection of rhesus macaques against simian immunodeficiency virus infection

AU - Carlson, J. R.

AU - McGraw, T. P.

AU - Keddie, E.

AU - Yee, J. L.

AU - Rosenthal, A.

AU - Luciw, Paul A

AU - Dickover, R.

AU - Donovan, R.

AU - Luciw, P. A.

AU - Jennings, M. B.

AU - Gardner, M. B.

PY - 1990

Y1 - 1990

N2 - Rhesus macaques (Macaca mulatta) immunized with an inactivated whole SIV(mac) vaccine and muramyl dipeptide (MDP), incomplete Freund's adjuvant (IFA), or aqueous suspension were challenged intravenously with 0.1 TCID50 of cell-free SIV(mac). Whereas virus was readily recovered from the peripheral blood lymphocytes of 10 of 10 nonvaccinated controls following this challenge dose, virus was not recovered from the three animals that received the vaccine with MDP nor from one of two animals that received the vaccine with IFA and one of three animals that received the aqueous vaccine. The animals that were protected against challenge were those that had detectable SIV antibody response to the envelop, both the outer glycoprotein (gp120) and the truncated transmembrane glycoprotein (gp31). Protected monkeys tended to have higher titers of syncytial inhibition antibody prior to challenge. An anamnestic response after challenge was observed only in the vaccinated monkeys that became infected. Vaccinated animals that became challenge-infected tended to live longer than infected controls. These results confirm those at two other primate centers and indicate that killed whole SIV vaccines can protect against low challenge doses of SIV and prevent early death in those monkeys that do become infected. The mechanism of this protection remains undetermined. This finding adds optimism to the possibility of an eventual AIDS vaccine.

AB - Rhesus macaques (Macaca mulatta) immunized with an inactivated whole SIV(mac) vaccine and muramyl dipeptide (MDP), incomplete Freund's adjuvant (IFA), or aqueous suspension were challenged intravenously with 0.1 TCID50 of cell-free SIV(mac). Whereas virus was readily recovered from the peripheral blood lymphocytes of 10 of 10 nonvaccinated controls following this challenge dose, virus was not recovered from the three animals that received the vaccine with MDP nor from one of two animals that received the vaccine with IFA and one of three animals that received the aqueous vaccine. The animals that were protected against challenge were those that had detectable SIV antibody response to the envelop, both the outer glycoprotein (gp120) and the truncated transmembrane glycoprotein (gp31). Protected monkeys tended to have higher titers of syncytial inhibition antibody prior to challenge. An anamnestic response after challenge was observed only in the vaccinated monkeys that became infected. Vaccinated animals that became challenge-infected tended to live longer than infected controls. These results confirm those at two other primate centers and indicate that killed whole SIV vaccines can protect against low challenge doses of SIV and prevent early death in those monkeys that do become infected. The mechanism of this protection remains undetermined. This finding adds optimism to the possibility of an eventual AIDS vaccine.

UR - http://www.scopus.com/inward/record.url?scp=0025223143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025223143&partnerID=8YFLogxK

M3 - Article

C2 - 2078406

AN - SCOPUS:0025223143

VL - 6

SP - 1239

EP - 1246

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 11

ER -